These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33755732)

  • 41. Graves' orbitopathy development in thyroid cancer patients: a 16-year nationwide cohort study in South Korea.
    Kim M; Lee J; Hwang YB; Kang J; Ahn HY; Lee JK
    Eye (Lond); 2024 Oct; 38(15):2955-2959. PubMed ID: 38942911
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
    Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
    Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics.
    Kim S; Bang JI; Boo D; Kim B; Choi IY; Ko S; Yoo IR; Kim K; Kim J; Joo Y; Ryoo HG; Paeng JC; Park JM; Jang W; Kim B; Chung Y; Yang D; Yoo S; Lee HY
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3547-3556. PubMed ID: 35362796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.
    Reiners C; Schneider R; Platonova T; Fridman M; Malzahn U; Mäder U; Vrachimis A; Bogdanova T; Krajewska J; Elisei R; Vaisman F; Mihailovic J; Costa G; Drozd V
    Front Endocrinol (Lausanne); 2020; 11():381. PubMed ID: 32754115
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Are we really at the dawn of understanding sporadic pediatric thyroid carcinoma?
    Cordioli MI; Moraes L; Cury AN; Cerutti JM
    Endocr Relat Cancer; 2015 Dec; 22(6):R311-24. PubMed ID: 26307021
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult.
    Zhao X; Chen M; Qi X; Zhu H; Yang G; Guo Y; Dong Q; Yang Q
    Front Endocrinol (Lausanne); 2021; 12():805194. PubMed ID: 35154006
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
    Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
    Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk Factors for Indeterminate Response After Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer.
    Jeong E; Yoon JK; Lee SJ; Soh EY; Lee J; An YS
    Clin Nucl Med; 2019 Sep; 44(9):714-718. PubMed ID: 31162260
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of thyroid cancer after exposure to 131I in childhood.
    Cardis E; Kesminiene A; Ivanov V; Malakhova I; Shibata Y; Khrouch V; Drozdovitch V; Maceika E; Zvonova I; Vlassov O; Bouville A; Goulko G; Hoshi M; Abrosimov A; Anoshko J; Astakhova L; Chekin S; Demidchik E; Galanti R; Ito M; Korobova E; Lushnikov E; Maksioutov M; Masyakin V; Nerovnia A; Parshin V; Parshkov E; Piliptsevich N; Pinchera A; Polyakov S; Shabeka N; Suonio E; Tenet V; Tsyb A; Yamashita S; Williams D
    J Natl Cancer Inst; 2005 May; 97(10):724-32. PubMed ID: 15900042
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma.
    Reiners C; Biko J; Haenscheid H; Hebestreit H; Kirinjuk S; Baranowski O; Marlowe RJ; Demidchik E; Drozd V; Demidchik Y
    J Clin Endocrinol Metab; 2013 Jul; 98(7):3039-48. PubMed ID: 23616148
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Mizowaki T
    Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in the pulmonary function test after radioactive iodine treatment in patients with pulmonary metastases of differentiated thyroid cancer.
    Jang EK; Kim WG; Kim HC; Huh JW; Kwon H; Choi YM; Jeon MJ; Kim TY; Shong YK; Ryu JS; Kim WB
    PLoS One; 2015; 10(4):e0125114. PubMed ID: 25923702
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk of second malignancies among survivors of pediatric thyroid cancer.
    Adly MH; Sobhy M; Rezk MA; Ishak M; Afifi MA; Shafie AE; Ali MA; Zekri W; Alfaar AS; Rashed WM
    Int J Clin Oncol; 2018 Aug; 23(4):625-633. PubMed ID: 29492793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.
    Molenaar RJ; Sidana S; Radivoyevitch T; Advani AS; Gerds AT; Carraway HE; Angelini D; Kalaycio M; Nazha A; Adelstein DJ; Nasr C; Maciejewski JP; Majhail NS; Sekeres MA; Mukherjee S
    J Clin Oncol; 2018 Jun; 36(18):1831-1839. PubMed ID: 29252123
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer.
    Yu CY; Saeed O; Goldberg AS; Farooq S; Fazelzad R; Goldstein DP; Tsang RW; Brierley JD; Ezzat S; Thabane L; Goldsmith CH; Sawka AM
    Thyroid; 2018 Dec; 28(12):1662-1673. PubMed ID: 30370820
    [No Abstract]   [Full Text] [Related]  

  • 56. Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study.
    Wu W; Li S; Xu K; Meng Z
    Endokrynol Pol; 2023; 74(3):260-270. PubMed ID: 37335064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea.
    Ahn HY; Chae JE; Moon H; Noh J; Park YJ; Kim SG
    Endocrinol Metab (Seoul); 2020 Dec; 35(4):811-819. PubMed ID: 33212545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radioactive Iodine Therapy Did Not Significantly Increase the Incidence and Recurrence of Subsequent Breast Cancer.
    Ahn HY; Min HS; Yeo Y; Ma SH; Hwang Y; An JH; Choi HS; Keam B; Im SA; Park DJ; Park IA; Noh DY; Youn YK; Chung JK; Cho BY; Park SK; Park YJ
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3486-93. PubMed ID: 26147607
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers.
    Chuang SC; Hashibe M; Yu GP; Le AD; Cao W; Hurwitz EL; Rao JY; Neugut AI; Zhang ZF
    Cancer Lett; 2006 Jul; 238(1):42-52. PubMed ID: 16039041
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thyroid cancer in infants and adolescents after Chernobyl.
    Reiners C; Demidchik YE; Drozd VM; Biko J
    Minerva Endocrinol; 2008 Dec; 33(4):381-95. PubMed ID: 18923372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.